[go: up one dir, main page]

AR025691A1 - USE OF CSAIDS IN INFECTIONS BY RINOVIRUS - Google Patents

USE OF CSAIDS IN INFECTIONS BY RINOVIRUS

Info

Publication number
AR025691A1
AR025691A1 ARP000104866A ARP000104866A AR025691A1 AR 025691 A1 AR025691 A1 AR 025691A1 AR P000104866 A ARP000104866 A AR P000104866A AR P000104866 A ARP000104866 A AR P000104866A AR 025691 A1 AR025691 A1 AR 025691A1
Authority
AR
Argentina
Prior art keywords
rinovirus
csaids
infections
symptoms
csbp
Prior art date
Application number
ARP000104866A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR025691A1 publication Critical patent/AR025691A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente está dirigida al uso de un inhibidor de CSBP/p38 para el tratamiento de los síntomas del resfriado comun y de la exacerbacion de los síntomasasociados con el mismo en personas.This is directed to the use of a CSBP / p38 inhibitor for the treatment of symptoms of the common cold and the exacerbation of symptoms associated with it in people.

ARP000104866A 1999-09-17 2000-09-17 USE OF CSAIDS IN INFECTIONS BY RINOVIRUS AR025691A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17

Publications (1)

Publication Number Publication Date
AR025691A1 true AR025691A1 (en) 2002-12-11

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104866A AR025691A1 (en) 1999-09-17 2000-09-17 USE OF CSAIDS IN INFECTIONS BY RINOVIRUS

Country Status (17)

Country Link
EP (1) EP1223924A4 (en)
JP (1) JP2003516314A (en)
KR (1) KR20020032591A (en)
CN (1) CN1382044A (en)
AR (1) AR025691A1 (en)
AU (1) AU7584500A (en)
BR (1) BR0014041A (en)
CA (1) CA2385722A1 (en)
CO (1) CO5200855A1 (en)
CZ (1) CZ2002939A3 (en)
HU (1) HUP0204333A3 (en)
IL (1) IL148329A0 (en)
NO (1) NO20021301L (en)
PL (1) PL363116A1 (en)
TR (1) TR200200673T2 (en)
WO (1) WO2001019322A2 (en)
ZA (1) ZA200202060B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002528506A (en) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine
JP2003514899A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
ES2241675T3 (en) 1999-11-23 2005-11-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSPB / P38 QUINASA INHIBITORS.
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002060869A2 (en) * 2000-10-19 2002-08-08 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
ES2302925T3 (en) * 2002-03-20 2008-08-01 Elan Pharma International Limited COMPOSITIONS OF NANOPARTICULES OF PROTEIN QUINASA INHIBITORS ACTIVATED BY MYTHOGEN (MAP).
PL372963A1 (en) * 2002-04-05 2005-08-08 Boehringer Ingelheim Pharma Gmb & Co.Kg Method of treating mucus hypersecretion
JP2005538066A (en) * 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Novel pharmaceutical composition using novel anticholinergic agent and p38 kinase inhibitor
JP4593953B2 (en) * 2004-03-30 2010-12-08 杏林製薬株式会社 Rhinovirus infection prophylaxis
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
DK2276505T3 (en) * 2008-03-20 2013-11-25 Krister Tano Nose Spray Or Nasal Drops For Treating A Cold
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102573886A (en) * 2009-09-17 2012-07-11 相互制药公司 Method of treating asthma with antiviral agents
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (en) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Use of p38 mapk inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6469018B1 (en) * 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
NO20021301D0 (en) 2002-03-15
EP1223924A2 (en) 2002-07-24
HUP0204333A3 (en) 2004-07-28
IL148329A0 (en) 2002-09-12
CN1382044A (en) 2002-11-27
TR200200673T2 (en) 2002-12-23
BR0014041A (en) 2003-07-15
HUP0204333A2 (en) 2003-05-28
CA2385722A1 (en) 2001-03-22
WO2001019322A3 (en) 2001-10-04
KR20020032591A (en) 2002-05-03
NO20021301L (en) 2002-05-16
CO5200855A1 (en) 2002-09-27
EP1223924A4 (en) 2004-07-14
ZA200202060B (en) 2003-05-28
JP2003516314A (en) 2003-05-13
WO2001019322A2 (en) 2001-03-22
PL363116A1 (en) 2004-11-15
AU7584500A (en) 2001-04-17
CZ2002939A3 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
AR025691A1 (en) USE OF CSAIDS IN INFECTIONS BY RINOVIRUS
ES2154741T3 (en) USE OF CD23 UNION AGENTS IN THE TREATMENT OF AUTOIMMUNE DISEASES.
UY28258A1 (en) THERAPEUTIC TREATMENT
ECSP045081A (en) DERIVATIVES OF 1,8-NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
AR056306A1 (en) ORTHROMBEMIC CRYSTAL FORM OF ASENAPINE MALEATE, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE TREATMENT OF MENTAL DISORDERS
ECSP055851A (en) DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
TR200002759T2 (en) Cabergoline use in the treatment of leg numbness syndrome.
CY1112317T1 (en) RAPID CRYSTAL FORM OF A PYRIDASIN [4,5-B] INDOLIS PRODUCER
BR0306820A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papillomavirus infections.
ES2202855T3 (en) USE OF 5HT3 ANTAGONISTS TO PROMOTE INTESTINAL WASHING.
AR027945A1 (en) USE OF PRAMIPEXOL IN THE TREATMENT OF ADDICTION DISORDERS
AR043660A1 (en) THE TREATMENT OF ALZHEIMER'S DISEASE
BR9807523A (en) Quinoxalins in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS.
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
UY29170A1 (en) REPLACED ADENINS AND USES OF THE SAME
AR028772A1 (en) 5-AMINOALQUIL-PIRAZOL [4,3-D] PYRIMIDINS
BRPI0415232A (en) use of hypothermic xenon to treat neonatal asphyxia
UY27031A1 (en) USE OF DOPAMINE D4 RECEPTOR SELECTIVE AGONISTS TO TREAT SEXUAL DYSFUNCTION
AR028411A1 (en) SEQUENCES OF NUCLENTIDS RELATED TO THE INCREASE OR DECREASE OF THE OVULATION ENDICE IN MAMEFEROS
UY26846A1 (en) PIRROLIDINE DERIVATIVES
ES2182987T3 (en) USE OF PIRROLIDINE DERIVATIVES FOR THE TREATMENT OF ALCOHOLISM.
UY27312A1 (en) NEW HETEROCICLOS 3
DK1450782T3 (en) Use of a combination preparation comprising propionyl L-carnitine and additional drugs for the treatment of erectile dysfunction
BRPI0416202A (en) phosphodiesterase inhibitor formulations v
BR0214848A (en) Glioblastoma treatment with Thymosin alfa-1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal